93 96
[5]
Raman JD, Ng CK, Boorjian SA, Vaughan Jr ED, Sosa RE, Scherr DS. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictivefactors andpathology. BJU Int 2005;96: 1031–5.
[6]
Wenbin D, Zhuo C, Zhibing M, et al. The effect of smoking on the risk of gallbladder cancer: a meta-analysis of observational studies. Eur J Gastroenterol Hepatol 2013;25:373–9.[7]
Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gas- troenterol Clin North Am 2010;39:331–42.[8]
Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract can- cer N Engl J Med 2010;362:1273–81.[9]
Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010;116:3127–34.
http://dx.doi.org/10.1016/j.euf.2014.12.002E U R O P E A N
U R O L O G Y
F O C U S
1
( 2 0 1 5
)
9 0 – 9 3
93